Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Matteelli

Showing results (191-200 of 203) with videos related to

Pageof 21
Sort By:
Antibiotics (Basel, Switzerland)|November 27, 2021
Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis NetworkLia D'Ambrosio, Rosella Centis, Claudia C Dobler, et al.
The European Respiratory Journal|March 12, 2016
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TBSimon Tiberi, Marie-Christine Payen, Giovanni Sotgiu, et al.
The European Respiratory Journal|March 25, 2014
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statementChristoph Lange, Ibrahim Abubakar, Jan-Willem C Alffenaar, et al.
The European Respiratory Journal|April 15, 2016
Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TBSimon Tiberi, Giovanni Sotgiu, Lia D'Ambrosio, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 25, 2016
Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant TuberculosisSimon Tiberi, Giovanni Sotgiu, Lia D'Ambrosio, et al.
The Lancet Regional Health. Europe|December 16, 2025
Correction to Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study Lancet Reg Health Eur 57 (2025) 101416 LLRHEUROPE-D-25-00310Martina Sester, Neus Altet-Gomez, Åse Bengaard Andersen, et al.
The Lancet Regional Health. Europe|August 18, 2025
Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet studyMartina Sester, Neus Altet-Gomez, Åse Bengaard Andersen, et al.
Autoimmunity Reviews|May 8, 2020
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, ItalyPaola Toniati, Simone Piva, Marco Cattalini, et al.
The European Respiratory Journal|March 21, 2015
Towards tuberculosis elimination: an action framework for low-incidence countriesKnut Lönnroth, Giovanni Battista Migliori, Ibrahim Abubakar, et al.
The European Respiratory Journal|September 26, 2015
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countriesHaileyesus Getahun, Alberto Matteelli, Ibrahim Abubakar, et al.
Pageof 21

Showing results (191-200 of 203) with videos related to

Sort By:
Pageof 21
Antibiotics (Basel, Switzerland)|November 27, 2021
Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis NetworkLia D'Ambrosio, Rosella Centis, Claudia C Dobler, et al.
The European Respiratory Journal|March 12, 2016
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TBSimon Tiberi, Marie-Christine Payen, Giovanni Sotgiu, et al.
The European Respiratory Journal|March 25, 2014
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statementChristoph Lange, Ibrahim Abubakar, Jan-Willem C Alffenaar, et al.
The European Respiratory Journal|April 15, 2016
Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TBSimon Tiberi, Giovanni Sotgiu, Lia D'Ambrosio, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 25, 2016
Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant TuberculosisSimon Tiberi, Giovanni Sotgiu, Lia D'Ambrosio, et al.
The Lancet Regional Health. Europe|December 16, 2025
Correction to Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study Lancet Reg Health Eur 57 (2025) 101416 LLRHEUROPE-D-25-00310Martina Sester, Neus Altet-Gomez, Åse Bengaard Andersen, et al.
The Lancet Regional Health. Europe|August 18, 2025
Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet studyMartina Sester, Neus Altet-Gomez, Åse Bengaard Andersen, et al.
Autoimmunity Reviews|May 8, 2020
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, ItalyPaola Toniati, Simone Piva, Marco Cattalini, et al.
The European Respiratory Journal|March 21, 2015
Towards tuberculosis elimination: an action framework for low-incidence countriesKnut Lönnroth, Giovanni Battista Migliori, Ibrahim Abubakar, et al.
The European Respiratory Journal|September 26, 2015
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countriesHaileyesus Getahun, Alberto Matteelli, Ibrahim Abubakar, et al.
Pageof 21